Identifying Drug Sensitivity Subnetworks with NETPHIX

Summary Phenotypic heterogeneity in cancer is often caused by different patterns of genetic alterations. Understanding such phenotype-genotype relationships is fundamental for the advance of personalized medicine. We develop a computational method, named NETPHIX (NETwork-to-PHenotype association with eXclusivity) to identify subnetworks of genes whose genetic alterations are associated with drug response or other continuous cancer phenotypes. Leveraging interaction information among genes and properties of cancer mutations such as mutual exclusivity, we formulate the problem as an integer linear program and solve it optimally to obtain a subnetwork of associated genes. Applied to a large-scale drug screening dataset, NETPHIX uncovered gene modules significantly associated with drug responses. Utilizing interaction information, NETPHIX modules are functionally coherent and can thus provide important insights into drug action. In addition, we show that modules identified by NETPHIX together with their association patterns can be leveraged to suggest drug combinations.

[1]  Min Chen,et al.  Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A. , 2010, International journal of oncology.

[2]  Andreas Schlicker,et al.  Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. , 2014, Cell reports.

[3]  H. Lenz,et al.  The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. , 2011, Cancer research.

[4]  Roded Sharan,et al.  BeWith: A Between-Within method to discover relationships between cancer modules via integrated analysis of mutual exclusivity, co-occurrence and functional interactions , 2017, PLoS Comput. Biol..

[5]  Florence Demenais,et al.  SigMod: an exact and efficient method to identify a strongly interconnected disease‐associated module in a gene network , 2017, Bioinform..

[6]  Dennis Vitkup,et al.  Diverse types of genetic variation converge on functional gene networks involved in schizophrenia , 2012, Nature Neuroscience.

[7]  Michael P. Morrissey,et al.  Pharmacogenomic agreement between two cancer cell line data sets , 2015, Nature.

[8]  Tero Aittokallio,et al.  Machine learning and feature selection for drug response prediction in precision oncology applications , 2018, Biophysical Reviews.

[9]  C J Gomer,et al.  Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. , 2001, Cancer research.

[10]  Hongzhe Li,et al.  In Response to Comment on "Network-constrained regularization and variable selection for analysis of genomic data" , 2008, Bioinform..

[11]  Joshua A. Bittker,et al.  Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.

[12]  Erhan Bilal,et al.  DREAMTools: a Python package for scoring collaborative challenges , 2015, F1000Research.

[13]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[14]  Chris Sander,et al.  Using MEMo to Discover Mutual Exclusivity Modules in Cancer , 2013, Current protocols in bioinformatics.

[15]  Trey Ideker,et al.  Classifying tumors by supervised network propagation , 2018, Bioinform..

[16]  Kuang-Hung Cheng,et al.  SMAD4 Loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells , 2014, BMC Cancer.

[17]  Yiming Wang,et al.  On imposing connectivity constraints in integer programs , 2017, Mathematical Programming.

[18]  Salim A. Chowdhury,et al.  IDENTIFICATION OF COORDINATELY DYSREGULATED SUBNETWORKS IN COMPLEX PHENOTYPES by SALIM , 2010 .

[19]  T. Fojo,et al.  Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. , 2005, Cancer research.

[20]  J. Guevara,et al.  The Role of CYP2E1 in the Drug Metabolism or Bioactivation in the Brain , 2017, Oxidative medicine and cellular longevity.

[21]  Sheng Wang,et al.  Identification of pathways associated with chemosensitivity through network embedding , 2017, bioRxiv.

[22]  Jin-Rong Zhou,et al.  Smad4 inactivation promotes malignancy and drug resistance of colon cancer. , 2011, Cancer research.

[23]  K. O'Byrne,et al.  Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi , 2018, Front. Oncol..

[24]  Gennaro Ciliberto,et al.  Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. , 2015, Free radical biology & medicine.

[25]  Matteo Fischetti,et al.  Thinning out Steiner trees: a node-based model for uniform edge costs , 2017, Math. Program. Comput..

[26]  Jinyu Chen,et al.  A Survey and Systematic Assessment of Computational Methods for Drug Response Prediction , 2019, bioRxiv.

[27]  Kirsten Grønbæk,et al.  Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. , 2012, Leukemia research reports.

[28]  Laura M. Heiser,et al.  A community effort to assess and improve drug sensitivity prediction algorithms , 2014, Nature Biotechnology.

[29]  Caroline Robert,et al.  P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. , 2017, European journal of cancer.

[30]  Teresa M. Przytycka,et al.  Module Cover - A New Approach to Genotype-Phenotype Studies , 2012, Pacific Symposium on Biocomputing.

[31]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[32]  Teresa M. Przytycka,et al.  WeSME: uncovering mutual exclusivity of cancer drivers and beyond , 2016, Bioinform..

[33]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[34]  T. Ideker,et al.  Network-based classification of breast cancer metastasis , 2007, Molecular systems biology.

[35]  Trey Ideker,et al.  Genotype to phenotype via network analysis. , 2013, Current opinion in genetics & development.

[36]  Tingting Chen,et al.  Genetic Interaction-Based Biomarkers Identification for Drug Resistance and Sensitivity in Cancer Cells , 2019, Molecular therapy. Nucleic acids.

[37]  Richard M. Karp,et al.  DEGAS: De Novo Discovery of Dysregulated Pathways in Human Diseases , 2010, PloS one.

[38]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[39]  Xiaoting Yu,et al.  Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer , 2018, Clinical Cancer Research.

[40]  Huimin Bian,et al.  Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene. , 2018, Cancer discovery.

[41]  Teresa M. Przytycka,et al.  Identifying Causal Genes and Dysregulated Pathways in Complex Diseases , 2011, PLoS Comput. Biol..

[42]  M. Fukumoto,et al.  KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer , 2008, British Journal of Cancer.

[43]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[44]  Andrew M. Gross,et al.  Network-based stratification of tumor mutations , 2013, Nature Methods.

[45]  Gabriela Alexe,et al.  Characterizing genomic alterations in cancer by complementary functional associations , 2016, Nature Biotechnology.

[46]  Niko Beerenwinkel,et al.  TiMEx: a waiting time model for mutually exclusive cancer alterations , 2015, Bioinform..

[47]  Michèle Rouleau,et al.  Pharmacogenomics of Human Uridine Diphospho‐Glucuronosyltransferases and Clinical Implications , 2014, Clinical pharmacology and therapeutics.

[48]  Samra Turajlic,et al.  BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling , 2014, Science Signaling.

[49]  Francesco Iorio,et al.  Logic models to predict continuous outputs based on binary inputs with an application to personalized cancer therapy , 2016, Scientific Reports.

[50]  Han C. Dan,et al.  Inhibition of cisplatin-resistant head and neck squamous cell carcinoma by combination of Afatinib with PD0325901, a MEK inhibitor. , 2019, American journal of cancer research.

[51]  Dorit S. Hochbaum,et al.  Efficient algorithms to discover alterations with complementary functional association in cancer , 2018, RECOMB.

[52]  Marco Chiarandini,et al.  An Efficient Branch and Cut Algorithm to Find Frequently Mutated Subnetworks in Cancer , 2016, WABI.

[53]  Roded Sharan,et al.  Network-based approaches elucidate differences within APOBEC and clock-like signatures in breast cancer , 2019, Genome Medicine.

[54]  Teresa M. Przytycka,et al.  Understanding Genotype-Phenotype Effects in Cancer via Network Approaches , 2016, PLoS Comput. Biol..

[55]  Eli Upfal,et al.  Discovery of Mutated Subnetworks Associated with Clinical Data in Cancer , 2011, Pacific Symposium on Biocomputing.

[56]  Wei Zheng,et al.  dmGWAS: dense module searching for genome-wide association studies in protein-protein interaction networks , 2011, Bioinform..

[57]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[58]  Kenneth H. Buetow,et al.  CREBBP mutations in relapsed acute lymphoblastic leukaemia , 2011, Nature.

[59]  Yoshinobu Kawahara,et al.  Efficient network-guided multi-locus association mapping with graph cuts , 2012, Bioinform..

[60]  Teresa M. Przytycka,et al.  MEMCover: integrated analysis of mutual exclusivity and functional network reveals dysregulated pathways across multiple cancer types , 2015, Bioinform..

[61]  Krishna R. Kalari,et al.  Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance , 2016, Genome Biology.